Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Resources

Aug 15, 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Author(s): Lynda Charters Fact checked by: Karen S. DeLoss, OD, FAAO Key Takeaways Ocular exams can reveal cardiovascular health issues, especially in women, whose symptoms often differ from traditional expectations.…

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

Aug 12, 2025

Cosmetic procedures associated with serious ophthalmologic complications

Author(s): Lynda Charters Key Takeaways Minimally invasive cosmetic procedures can cause rare but severe ophthalmological complications, including irreversible vision loss from central retinal artery occlusion. Prevention is crucial due to…

Cosmetic procedures associated with serious ophthalmologic complications

Aug 11, 2025

EyePoint completes enrollment in second phase 3 trial of sustained-release AMD therapy

ByJay S. Duker, MD ByAlex Young ByAnthony DeFino Fact checked by Christine Klimanskis, ELS Key takeaways: More than 400 patients have been enrolled in the LUCIA trial investigating Duravyu. EyePoint…

EyePoint completes enrollment in second phase 3 trial of sustained-release AMD therapy

Aug 11, 2025

This common fruit has over 1,600 compounds that boost brain, heart, and gut health

Published August 6, 2025 | Originally published on ScienceDaily Top Health A new article appearing in the current issue of the peer-reviewed Journal of Agriculture and Food Chemistry explores the concept of “superfoods” and makes…

This common fruit has over 1,600 compounds that boost brain, heart, and gut health

Aug 6, 2025

Study supports Iluvien as ‘long-acting option’ in diabetic macular edema

Key takeaways: The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A post hoc analysis achieved its primary endpoint. LONG BEACH, Calif.…

Study supports Iluvien as ‘long-acting option’ in diabetic macular edema

Aug 5, 2025

Geographic Atrophy Patient Experience Research

A new study is being conducted on geographic atrophy. They would like to hear about your experience with the drug Izervay. This is a 60-minute phone interview. Please contact Grace,…

Geographic Atrophy Patient Experience Research

Jul 31, 2025

Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point

Author(s): Jordana Joy Key Takeaways LUMIFY Preservative Free eye drops are statistically non-inferior to LUMIFY in reducing ocular redness, with similar efficacy and safety profiles. The study involved 380 participants,…

Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point

Jul 28, 2025

VA-developed RainDrop Dispenser Aid aims to simplify use of single-use eye drops for patients with arthritis, tremors July 24, 2025

July 24, 2025 by Lynda Charters, Jordana Joy, Associate Editor Rain Eye Drops LLC announced the launch of a newly refined first-of-its-kind RainDrop Dispenser Aid created specifically for single-use preservative-free…

VA-developed RainDrop Dispenser Aid aims to simplify use of single-use eye drops for patients with arthritis, tremors July 24, 2025

Jul 24, 2025

Novel AI-powered retina tracker detects eye disease in under one second

By: The Endocrine Society A novel AI-powered retina tracker can analyze retinal images with near-perfect accuracy in under one second, according to a study being presented Monday at ENDO 2025, the…

Novel AI-powered retina tracker detects eye disease in under one second

Jul 24, 2025

Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial

By: Justin Cooper Fact checked by: Christine Klimanskis, ELS Key takeaways: Danegaptide could be an oral therapy for patients with moderate to severe nonproliferative diabetic retinopathy. The treatment was well…

Oral danegaptide for diabetic retinopathy successfully completes phase 1b trial

Jul 24, 2025

Survey finds majority of US patients delaying eye care despite experiencing poor eyesight, eye health

By: Jordana Joy, Associate Editor Survey participants cited cost concerns, perceived inevitability, and deprioritization as obstacles to receiving eye care.

Survey finds majority of US patients delaying eye care despite experiencing poor eyesight, eye health

Jul 24, 2025

FDA fast tracks one-time intravitreal gene therapy for geographic atrophy

By: Anthony DeFino Fact checked by: Christine Klimanskis, ELS Key takeaways: SAR446597 is designed to inhibit C1s and factor Bb in the complement pathway. Fast-track designation expedites the development and…

FDA fast tracks one-time intravitreal gene therapy for geographic atrophy

Jul 8, 2025

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Author(s): Martin David Harp Key Takeaways Alcon’s acquisition of LumiThera includes a PBM device for early and intermediate dry AMD, enhancing its non-invasive treatment portfolio. LumiThera’s PBM device demonstrated significant…

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Jul 8, 2025

Can you eye doctor predict an impending stroke?

A university study shows certain types of retina problems are early signs of stroke. Research scientists from the University of Sydney in Australia screened the eyes of 3,654 healthy adults…

Can you eye doctor predict an impending stroke?

Jul 3, 2025

Happy Independence Day

    The Macular Degeneration Association would like to wish everyone a safe and excellent 4th of July. The offices will be closed on Friday in observance of the 4th…

Happy Independence Day

Jun 30, 2025

36-month results from phase 1/2a clinical study of RG6501 released

Author(s): Kassi Filkins Key Takeaways RG6501 (OpRegen) cell therapy shows sustained visual acuity and retinal structure improvements in GA patients over 36 months. Extensive coverage of OpRegen therapy leads to…

36-month results from phase 1/2a clinical study of RG6501 released

Jun 30, 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Author(s): Glenn Yiu, MD, PhD Fact checked by: Sheryl Stevenson Frequent intravitreal injections for neovascular age-related macular degeneration present a long-term treatment burden, highlighting the need for innovative, durable solutions…

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Jun 23, 2025

Instant coffee can cause blindness, says report

Published in Food Science & Nutrition, the study examined a large genetic dataset of more than 5,00,000 people and used sophisticated genetic correlation and Mendelian randomisation to investigate the association…

Instant coffee can cause blindness, says report

Jun 19, 2025

ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial

By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Dry eye disease associated with systemic autoimmune or inflammatory conditions significantly improved with ILYX-002 after 15 days. ILYX-002 targets…

ILYX-002 rapidly improves immune-mediated dry eye disease in phase 2 trial

Jun 16, 2025

Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT

Author(s): Christine Curcio, PhD, Sheryl Stevenson Conferences|International SPECTRALIS Symposium – and Beyond From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer…

Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT

Jun 16, 2025

Cataract surgery may curb dementia, Alzheimer’s risk in those without anxiety, depression

By Justin Cooper Fact checked by Christine Klimanskis, ELS Key takeaways: Cataract surgery had a protective effect against overall dementia and Alzheimer’s, but not vascular dementia. There was no protection…

Cataract surgery may curb dementia, Alzheimer’s risk in those without anxiety, depression

Jun 16, 2025

Undiagnosed AMD prevalence in urban setting higher than national average

By Alex Young Fact checked by Eamon N. Dreisbach Key takeaways: A hospital in New York had a higher percentage of undiagnosed AMD compared with CDC reported values. Researchers hope…

Undiagnosed AMD prevalence in urban setting higher than national average

Jun 12, 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

Author(s): Sheryl Stevenson Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptyr; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED)1,2 brings…

FDA nod for acoltremon: What its approval means for clinicians and patients

Jun 10, 2025

Press Release PAO Action Week

Press Release   Hello, The Macular Degeneration Association is one of the 1,200+ patient advocacy organizations (PAOs) in the United States working to support patients and caregivers. However, many people…

Press Release PAO Action Week

Jun 10, 2025

Home OCT a ‘safety net’ for reducing treatment burden in wet AMD

ByAnthony DeFino Fact checked byChristine Klimanskis, ELS Key takeaways: Home OCT may help patients achieve extended dosing intervals through consistent fluid evaluation. Scans are reviewed by AI through a cloud-based…

Home OCT a ‘safety net’ for reducing treatment burden in wet AMD

Jun 2, 2025

Stop Smoking Now to Protect Your Vision, Experts Warn

Edited by Shrabasti Bhattacharya TOPLINE: Current smokers faced up to 12-fold higher risk for age-related macular degeneration, a threefold higher risk for primary open-angle glaucoma, and a fourfold higher risk…

Stop Smoking Now to Protect Your Vision, Experts Warn

May 27, 2025

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

Author(s): Emily Kaiser Maharjan Key Takeaways Aldeyra’s phase 3 trial of reproxalap showed statistical superiority in reducing ocular discomfort compared to the vehicle, supporting NDA resubmission. The unique chamber trial…

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

May 26, 2025

Remember and Honor Our Fallen Heroes

“Their sacrifice was the ultimate act of love for their country. May we always remember them.” — Unknown

Remember and Honor Our Fallen Heroes

May 16, 2025

PARTICIPATE IN A MARKET RESEARCH STUDY ON VISUAL IMPAIRMENTS

Exafield US, a healthcare market research company based in the USA, is conducting a study on visual impairments and would love to hear your opinions! We are seeking English-speaking individuals…

PARTICIPATE IN A MARKET RESEARCH STUDY ON VISUAL IMPAIRMENTS

May 15, 2025

Living with GA: How patients in the US and Western Europe cope

Living with GA: How patients in the US and Western Europe cope Author(s): Lynda Charters Key Takeaways Geographic atrophy significantly impacts patients’ daily activities, independence, and mental health, necessitating coping…

Living with GA: How patients in the US and Western Europe cope

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.